

CLINICAL TRIAL PROTOCOL

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients with Active Ulcerative Colitis

Protocol Number:	CTJ301UC201
Investigational Medicinal Product:	TJ301 (solution for injection), also referred to as FE 999301 and Olamkicept
Indication:	Active Ulcerative Colitis
Phase:	2
Investigators:	Multicenter, international, across Mainland China, Taiwan, Republic of Korea and Australia
Coordinating Investigator	Prof. Dr. Minhu Chen Chair, Department of Gastroenterology and Hepatology Vice President The First Affiliated Hospital, Sun Yat-sen University 58 Zhongshan Road, Guangzhou, China
Expert committee	Prof. Dr. Stefan Schreiber Institute for Clinical Molecular Biology University Hospital Schleswig-Holstein Schittenhelmstrasse 12, 24105 Kiel, Germany
Name and Address of Sponsor:	Leading Biopharm Limited Sponsor Contact: Yin Liu Suite 802, OmniVision Park West Tower 88 Shangke Road, Pudong, Shanghai 201210, China Tel: + 86 135 0178 1723
GCP Statement:	This trial will be performed in compliance with GCP.

The information in this document is confidential and is proprietary to Leading Biopharm Limited. It is understood that information in this document shall not be disclosed to any third party, in any form, without prior written consent of an authorised officer of Leading Biopharm Limited.